ArticleHealth science reports2025
Elevated Methylation Contributes to Suppressed Expression of Special AT-Rich Sequence-Binding Protein 2 in Colorectal Cancer: A Gene-Disease Association Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Special AT-rich sequence-binding protein 2 (SATB2) is a commonly used clinical marker for colorectal cancer (CRC) diagnosis. It has been reported that SATB2 expression is significantly downregulated in CRC tissues; however, the underlying mechanism remains unclear. Methylation represents one of the key epigenetic modifications involved in regulating gene expression. The objective of this study was to investigate the relationship between the methylation status of SATB2 and its expression levels in CRC tissues. Methods: We first investigated the methylation status and expression level of SATB2 via the use of transcriptional and methylation data from CRC patients in The Cancer Genome Atlas via bioinformatics analysis. Next, we explored the methylation status of the SATB2 promoter and SATB2 expression patterns in the collected CRC tumor and adjacent normal tissues, as well as different cell lines, via methylation-specific PCR and quantitative PCR. Next, the normal colorectal FHC cell line and CRC cell lines were treated with azacytidine (AZA) to investigate whether the mRNA expression of SATB2 could be restored by demethylating agents. Finally, associations between clinicopathological characteristics and SATB2 methylation status were analyzed. Results: The results of both bioinformatics and experimental analyses demonstrated that SATB2 expression was downregulated in CRC tumor tissues and that SATB2 hypermethylation was detected in various regions, including the promoter. The downregulated expression of SATB2 in CRC tumor tissues was significantly correlated with SATB2 hypermethylation, and the mRNA expression level of SATB2 significantly increased following AZA treatment in certain CRC cell lines. Additionally, the methylation state of SATB2 was correlated with tumor differentiation and metastasis. Conclusion: In summary, increased methylation levels contribute to decreased SATB2 expression in CRC, indicating the clinical relevance of SATB2 methylation as a potential therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.